Our previous findings elucidated that the hydroethanolic extract of Echium angustifolium M ill. aerial parts and its defatted (polar) fraction supported by bio-guided fractionation possessed potential anticancer and antioxidant activities, as well as other documented plant therapeutic uses. Consequently, the present study aimed to evaluate the hexane (non-polar) extract of E. angustifolium aerial parts for in vitro anticancer, antioxidant, and anti-inflammatory activities accompanied by characterization of its bioactive constituents using GC-M S and LC-ESI-M S techniques in order to gain a deeper understanding of this medicinal plant that could be developed as a phytomedicine. This extract exhibited high inhibition against HCT116 (IC 50 = 12 µg/mL) & HEPG2 (IC 50 = 18 µg/mL) cancer cell lines, with antioxidant and anti-inflammatory potentials. GC-M S of the analyzed extract led to identifying 24 volatile constituents, among them, ethyl esters of palmitic acid and linoleic acid were the most abundant oxygenated compounds. M eanwhile, 10 nonvolatile components were annotated by LC-ESI-M S comprising five phenolic acid derivatives, two lignans, echimidine, acetylshikonin, and quinic acid. M oreover, some of these phytoconstituents were identified in this plant species for the first time. These results justify using non-polar E. angustifolium extract as a possible source of anticancer, antioxidant, and anti-inflammatory agents, which can be better confirmed by further in vivo studies.